ECSP088403A - Formulacion farmaceutica de absorción oral y su método de administracion - Google Patents
Formulacion farmaceutica de absorción oral y su método de administracionInfo
- Publication number
- ECSP088403A ECSP088403A EC2008008403A ECSP088403A ECSP088403A EC SP088403 A ECSP088403 A EC SP088403A EC 2008008403 A EC2008008403 A EC 2008008403A EC SP088403 A ECSP088403 A EC SP088403A EC SP088403 A ECSP088403 A EC SP088403A
- Authority
- EC
- Ecuador
- Prior art keywords
- micelle
- pharmaceutical formulation
- aerosol
- formulation
- administration
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000010521 absorption reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- -1 alkali metal alkyl sulfate Chemical class 0.000 abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 239000000443 aerosol Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 239000000693 micelle Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 229920001400 block copolymer Polymers 0.000 abstract 1
- 238000002716 delivery method Methods 0.000 abstract 1
- 235000012054 meals Nutrition 0.000 abstract 1
- 210000002200 mouth mucosa Anatomy 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Una formulación farmacéutica para absorber por la mucosa oral que incluye una cantidad efectiva de (a) un agente farmacéutico en forma de micela combinada, (b) al menos unCompuesto formador de micela seleccionado del grupo de sulfato alquilo de metal alcalino y monooleato de sorbitan polioxietileno, (c) un copolímero bloque de polioxietileno y polioxipropileno, (d) al menos un compuesto formador de micela adicional y (e) un disolvente adecuado. La invención proporciona además un dispensador de dosis graduado (aerosol y no aerosol) que contiene la presente formulación y un método de administración de insulina con un dispensador de dosis graduado que incluye administrar dosis múltiples de una formulación que contiene insulina antes y después de cada comida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2005/001816 WO2007062494A1 (en) | 2005-11-30 | 2005-11-30 | Orally absorbed pharmaceutical formulation and method of administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088403A true ECSP088403A (es) | 2008-05-30 |
Family
ID=38091821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008403A ECSP088403A (es) | 2005-11-30 | 2008-04-25 | Formulacion farmaceutica de absorción oral y su método de administracion |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20090214657A1 (es) |
| EP (1) | EP1954242A4 (es) |
| JP (1) | JP2009517410A (es) |
| CN (1) | CN101309668A (es) |
| AP (1) | AP2008004447A0 (es) |
| AR (1) | AR057180A1 (es) |
| AU (1) | AU2005338631B2 (es) |
| BR (1) | BRPI0520704A2 (es) |
| CA (1) | CA2630578C (es) |
| EA (1) | EA200800979A1 (es) |
| EC (1) | ECSP088403A (es) |
| IL (1) | IL191531A0 (es) |
| NZ (1) | NZ567601A (es) |
| UY (1) | UY29905A1 (es) |
| WO (1) | WO2007062494A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009015456A1 (en) * | 2007-07-30 | 2009-02-05 | Generex Pharmaceuticals Inc. | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray |
| CN101422431B (zh) * | 2007-12-28 | 2011-03-23 | 上海医药工业研究院 | 胰岛素经鼻给药制剂 |
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| CN100594929C (zh) * | 2009-06-24 | 2010-03-24 | 薛南荣 | 口服胰岛素药物及其制备方法 |
| PH12011502708B1 (en) | 2009-07-06 | 2017-11-10 | Sanofi Aventis Deutschland | Insulin preparations containing methionine |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| BR112012016853A2 (pt) * | 2010-01-12 | 2017-10-17 | Novo Nordisk As | "composições farmacêuticas para administração oral de peptídeos de insulina". |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| USD645954S1 (en) * | 2010-05-21 | 2011-09-27 | Consort Medical Plc | Mechanical dosage counter apparatus |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| CN102228680B (zh) * | 2011-06-14 | 2013-02-27 | 中国人民解放军第三0二医院 | 胸腺肽的磷脂/胆盐复合胶束及其制备方法和制剂 |
| CA2827130A1 (en) * | 2011-06-27 | 2013-01-03 | Board Of Regents, The University Of Texas System | Toroidal pharmaceutical formulations |
| JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ２型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| EP3517122A1 (en) | 2013-04-03 | 2019-07-31 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
| US9687455B2 (en) | 2014-08-14 | 2017-06-27 | John Daniel Dobak | Sodium tetradecyl sulfate formulations for treatment of adipose tissue |
| DK3006045T3 (en) * | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| US9351945B1 (en) | 2015-02-27 | 2016-05-31 | John Daniel Dobak, III | Reduction of adipose tissue |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| EP3359181A1 (en) | 2015-10-07 | 2018-08-15 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide drugs |
| US11166912B2 (en) | 2016-03-03 | 2021-11-09 | Ctt Pharma Inc. | Orally administrable composition |
| US11298336B2 (en) | 2019-05-30 | 2022-04-12 | Soluble Technologies, Inc. | Water soluble formulation |
| US11786475B2 (en) | 2020-07-22 | 2023-10-17 | Soluble Technologies Inc. | Film-based dosage form |
| US12108809B1 (en) | 2022-04-15 | 2024-10-08 | Air 2, LLC | Aerosol pressurized delivery device and methods for manufacture and use of the same |
| EP4713057A1 (en) * | 2023-05-15 | 2026-03-25 | Air 2 LLC | Pressurized sublingual delivery device and methods for manufacture and use of the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
| WO1994008564A1 (en) * | 1992-10-08 | 1994-04-28 | Valery Yu Alakhov | Composition of antineoplastic agents incorporated in micelles |
| US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
| TW402506B (en) * | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
| DE19733651A1 (de) * | 1997-08-04 | 1999-02-18 | Boehringer Ingelheim Pharma | Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole |
| IL122084A (en) * | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
| US6063762A (en) * | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| US6017545A (en) * | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
| US6375975B1 (en) * | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
| US6451286B1 (en) * | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
| US6436367B1 (en) * | 1998-12-21 | 2002-08-20 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
| US6312665B1 (en) * | 1998-12-21 | 2001-11-06 | Generex Pharmaceuticals Incorporated | Aerosol formulations for buccal and pulmonary application |
| US7087215B2 (en) * | 1998-12-21 | 2006-08-08 | Generex Pharmaceuticals Incorporated | Methods of administering and enhancing absorption of pharmaceutical agents |
| AU5936400A (en) * | 1999-06-04 | 2000-12-28 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
-
2005
- 2005-11-30 US US12/085,783 patent/US20090214657A1/en not_active Abandoned
- 2005-11-30 CA CA2630578A patent/CA2630578C/en not_active Expired - Fee Related
- 2005-11-30 NZ NZ567601A patent/NZ567601A/en not_active IP Right Cessation
- 2005-11-30 AP AP2008004447A patent/AP2008004447A0/xx unknown
- 2005-11-30 CN CNA2005800520768A patent/CN101309668A/zh active Pending
- 2005-11-30 EA EA200800979A patent/EA200800979A1/ru unknown
- 2005-11-30 EP EP05814246A patent/EP1954242A4/en not_active Withdrawn
- 2005-11-30 AU AU2005338631A patent/AU2005338631B2/en not_active Ceased
- 2005-11-30 BR BRPI0520704-5A patent/BRPI0520704A2/pt not_active IP Right Cessation
- 2005-11-30 JP JP2008542566A patent/JP2009517410A/ja active Pending
- 2005-11-30 WO PCT/CA2005/001816 patent/WO2007062494A1/en not_active Ceased
-
2006
- 2006-11-08 UY UY29905A patent/UY29905A1/es not_active Application Discontinuation
- 2006-11-27 AR ARP060105216A patent/AR057180A1/es unknown
-
2008
- 2008-04-25 EC EC2008008403A patent/ECSP088403A/es unknown
- 2008-05-18 IL IL191531A patent/IL191531A0/en unknown
-
2012
- 2012-02-29 US US13/408,133 patent/US20120171259A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ567601A (en) | 2010-12-24 |
| US20090214657A1 (en) | 2009-08-27 |
| EP1954242A4 (en) | 2012-08-01 |
| US20120171259A1 (en) | 2012-07-05 |
| UY29905A1 (es) | 2007-05-31 |
| AR057180A1 (es) | 2007-11-21 |
| AP2008004447A0 (en) | 2008-04-30 |
| WO2007062494A1 (en) | 2007-06-07 |
| CA2630578A1 (en) | 2007-06-07 |
| CN101309668A (zh) | 2008-11-19 |
| AU2005338631A1 (en) | 2007-06-07 |
| EA200800979A1 (ru) | 2008-10-30 |
| AU2005338631B2 (en) | 2011-12-01 |
| IL191531A0 (en) | 2008-12-29 |
| EP1954242A1 (en) | 2008-08-13 |
| CA2630578C (en) | 2014-04-15 |
| BRPI0520704A2 (pt) | 2009-05-19 |
| JP2009517410A (ja) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29905A1 (es) | Formulación farmacéutica de absorción oral y su método de administración | |
| AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| HRP20060147B1 (hr) | Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu | |
| DK1257254T3 (da) | Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom | |
| TN2009000504A1 (en) | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray | |
| AR101593A2 (es) | Formulación superfina de formoterol | |
| WO2005041925A3 (en) | Compositions and dosage forms for enhanced absorption | |
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| AR034813A1 (es) | Composiciones farmaceuticas y uso de las mismas | |
| BRPI0606883A2 (pt) | composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única | |
| FR2878161B1 (fr) | Forme medicamenteuse orale, solide et concue pour eviter le mesusage | |
| MX2014004364A (es) | Composiciones que comprenden sulfato de salbutamol. | |
| SG149054A1 (en) | Multiparticulate formulations for oral delivery | |
| NO20083759L (no) | Doserings aerosoler for administrering av farmasoytiske preparater | |
| WO2013104892A8 (en) | Application of high dose compounds via inhalation | |
| WO2008106689A3 (en) | Breakthrough pain management | |
| DE60329968D1 (de) | Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren | |
| PE20011271A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
| WO2008079343A3 (en) | Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients | |
| TNSN07289A1 (en) | Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent | |
| JO3024B1 (ar) | صيغ أيروسول صيدلانية من الفرموتيرول وبكلوميتازون داي بروبيونات | |
| SE0401612L (sv) | Inhalator som använder balja | |
| WO2007020204A3 (en) | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate | |
| CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion | |
| CR9941A (es) | Formacion farmaceutica de absorcion oral y su metodo de administracion |